Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies.

Goetz ME, Hanfelt JJ, John SE, Bergquist SH, Loring DW, Quyyumi A, Clifford GD, Vaccarino V, Goldstein F, Johnson Nd TM, Kuerston R, Marcus M, Levey AI, Lah JJ.

Neuroepidemiology. 2019;53(3-4):187-200. doi: 10.1159/000501856. Epub 2019 Aug 27.

PMID:
31454799
2.
3.

Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center.

Hanfelt JJ, Peng L, Goldstein FC, Lah JJ.

Neurobiol Dis. 2018 Sep;117:62-71. doi: 10.1016/j.nbd.2018.05.025. Epub 2018 Jun 1.

4.

A clinical scale to communicate surgical urgency for traumatic brain injury: A preliminary study.

Sribnick EA, Hanfelt JJ, Dhall SS.

Surg Neurol Int. 2015 Jan 5;6:1. doi: 10.4103/2152-7806.148541. eCollection 2015.

5.

Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.

Donovan LE, Dammer EB, Duong DM, Hanfelt JJ, Levey AI, Seyfried NT, Lah JJ.

Alzheimers Res Ther. 2013 Jun 13;5(3):32. doi: 10.1186/alzrt186. eCollection 2013.

6.

Coprevalence of anxiety and depression with spasmodic dysphonia: a case-control study.

White LJ, Hapner ER, Klein AM, Delgaudio JM, Hanfelt JJ, Jinnah HA, Johns MM 3rd.

J Voice. 2012 Sep;26(5):667.e1-6. doi: 10.1016/j.jvoice.2011.08.011. Epub 2011 Dec 29.

7.

An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the National Alzheimer's Coordinating Center.

Hanfelt JJ, Wuu J, Sollinger AB, Greenaway MC, Lah JJ, Levey AI, Goldstein FC.

Am J Geriatr Psychiatry. 2011 Nov;19(11):940-50. doi: 10.1097/JGP.0b013e31820ee9d2.

8.

Coprevalence of tremor with spasmodic dysphonia: a case-control study.

White LJ, Klein AM, Hapner ER, Delgaudio JM, Hanfelt JJ, Jinnah HA, Johns MM 3rd.

Laryngoscope. 2011 Aug;121(8):1752-5. doi: 10.1002/lary.21872.

9.

Delay in diagnosis of diabetes is not the patient's fault.

Fraser LA, Twombly J, Zhu M, Long Q, Hanfelt JJ, Narayan KM, Wilson PW, Phillips LS.

Diabetes Care. 2010 Jan;33(1):e10. doi: 10.2337/dc09-1129. No abstract available.

10.

Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease.

Gozal YM, Duong DM, Gearing M, Cheng D, Hanfelt JJ, Funderburk C, Peng J, Lah JJ, Levey AI.

J Proteome Res. 2009 Nov;8(11):5069-79. doi: 10.1021/pr900474t.

11.

A robust method for finely stratified familial studies with proband-based sampling.

Wang M, Hanfelt JJ.

Biostatistics. 2009 Apr;10(2):364-73. doi: 10.1093/biostatistics/kxn043. Epub 2009 Feb 6.

12.

Testing for the presence of multiple sources of informative dropout in longitudinal data.

Crawford SB, Hanfelt JJ.

Stat Med. 2008 Sep 20;27(21):4175-89. doi: 10.1002/sim.3287.

PMID:
18613222
13.

Endoscopic mapping and surrogate markers for better surveillance in Barrett esophagus. A study of 700 biopsy specimens.

Bhargava P, Eisen GM, Holterman DA, Azumi N, Hartmann DP, Hanfelt JJ, Benjamin SB, Lippman ME, Montgomery EA.

Am J Clin Pathol. 2000 Oct;114(4):552-63.

PMID:
11026101
14.

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.

Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, Lawrence W, Hanfelt JJ, Hayes DF.

Ann Oncol. 2000 Jan;11(1):17-22.

15.

A modification of Simon's optimal design for phase II trials when the criterion is median sample size.

Hanfelt JJ, Slack RS, Gehan EA.

Control Clin Trials. 1999 Dec;20(6):555-66.

PMID:
10588296
16.
17.

Inference for odds ratio regression models with sparse dependent data.

Hanfelt JJ, Liang KY.

Biometrics. 1998 Mar;54(1):136-47.

PMID:
9544512
18.

Statistical approaches to experimental design and data analysis of in vivo studies.

Hanfelt JJ.

Breast Cancer Res Treat. 1997 Nov-Dec;46(2-3):279-302. Review.

PMID:
9478281
19.

Radiation therapy for rhabdomyosarcoma: local failure risk for Clinical Group III patients on Intergroup Rhabdomyosarcoma Study II.

Wharam MD, Hanfelt JJ, Tefft MC, Johnston J, Ensign LG, Breneman J, Donaldson SS, Fryer C, Gehan EA, Raney RB, Maurer HM.

Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):797-804.

PMID:
9240649

Supplemental Content

Loading ...
Support Center